On February 11, Eli Lilly announced that mirikizumab had been approved in China. This selectively targets the IL-23p19 subunit and was approved simultaneously for two indications: Crohn’s disease and ulcerative colitis.
Mirikizumab selectively targets the p19 subunit of IL-23, blocks its interaction with the IL-23 receptor, and inhibits release of pro-inflammatory cytokines and chemokines, thereby controlling inflammation.
The drug was first approved in Japan on March 27, 2023, and was subsequently approved by the EMA and the FDA for ulcerative colitis. From January to March 2025, the FDA, EMA, and Japan successively approved the drug for Crohn’s disease. According to Eli Lilly’s latest financial disclosure, mirikizumab generated USD 265 million in revenue in 2025, up more than 100% year over year and still ramping rapidly.
In October 2025, Eli Lilly disclosed Phase III clinical data for mirikizumab in Crohn’s disease and ulcerative colitis at the 25th Chinese Society of Gastroenterology Congress (CGC).
The VIVID study series is a Phase III program exploring the efficacy and safety of mirikizumab in adults with moderate to severe Crohn’s disease. At the meeting, Chinese subgroup data showed clinically meaningful improvement versus placebo in the composite primary endpoint and all key secondary endpoints in Chinese patients with moderate to severe active Crohn’s disease treated with mirikizumab.
VIVID-1 enrolled 152 Chinese adults with moderate to severe active Crohn’s disease. Consistent with the global population, the Chinese subgroup of VIVID-1 showed clinically meaningful improvement in the composite primary endpoint and all key secondary endpoints with mirikizumab versus placebo.
Compared with ustekinumab-treated patients, a higher proportion of mirikizumab-treated patients achieved endoscopic response (49.4% vs 27.5%), CDAI clinical remission (48.2% vs 20.0%), and CDAI clinical remission plus endoscopic response (32.5% vs 10.0%) at Week 52, showing robust and clinically meaningful improvement consistent with the overall population.
In the Chinese population, exposure-adjusted incidence rates of treatment-emergent adverse events, serious adverse events, and adverse events leading to discontinuation of study treatment were all lower in the mirikizumab group than in the placebo group. Most TEAEs in Chinese patients were mild to moderate in severity.
The LUCENT study series is a Phase III clinical program exploring the efficacy and safety of mirikizumab in adults with moderate to severe ulcerative colitis. At this congress, Eli Lilly released induction and maintenance data from the Chinese subgroup in LUCENT-1/2.
Data showed that Chinese patients with moderate to severe active ulcerative colitis treated with mirikizumab had higher clinical remission rates than placebo during both induction and maintenance, with improvement in other key secondary endpoints as well.
The Chinese subgroup data disclosed in this report mainly included the following.
In LUCENT-1, 184 Chinese adults with moderate to severe active ulcerative colitis were enrolled. At Week 12, the clinical remission rate was higher in the mirikizumab group than in the placebo group.
Among Chinese patients who responded to mirikizumab induction therapy, 50.0% achieved clinical remission at Week 52 during maintenance treatment, showing clinically meaningful improvement consistent with the overall population of LUCENT-2.
In Chinese patients, incidence of treatment-emergent adverse events was similar across groups. Compared with placebo, mirikizumab was associated with fewer serious adverse events and fewer discontinuations due to adverse events.
Insight database shows that eight IL-23-targeted drugs have now been approved in China. Five target the IL-23 p19 subunit: picankibart from Innovent, risankizumab from AbbVie, tildrakizumab introduced by CMS, guselkumab from Johnson & Johnson, and mirikizumab from Eli Lilly. Three others act by binding the IL-12/23 p40 subunit: ebdarokimab from Akeso, ustekinumab-QX001S from Qyuns/Qilu? and East China Pharmaceutical as a biosimilar, and Johnson & Johnson’s ustekinumab.